What it is
Sermorelin is a 29-amino-acid fragment of growth hormone releasing hormone, the signal the hypothalamus sends down to the pituitary gland when it wants growth hormone released.
The natural hormone is 44 amino acids long. Researchers found that the first 29 of them carry essentially all of the activity at the receptor, and that the remaining 15 can be left off without losing the effect. Sermorelin is that shortened version — the working end of a human hormone, made synthetically.
The distinction that matters most for a beginner: sermorelin is not growth hormone, and it does not supply any. It asks the pituitary gland to release its own. If the pituitary cannot respond — because it is damaged, or absent — sermorelin does nothing. That property is exactly why its first approved use was diagnostic.
What it is said to be good for
Two very different answers, and the gap between them is the whole story of this compound.
What it was approved for was growth hormone deficiency: as a test of whether a pituitary gland can release growth hormone when properly asked, and as a treatment for growth failure in children who lack the hormone. It was a pediatric endocrinology and diagnostic drug.
What it is marketed for now — in clinics and by research-chemical sellers — is adult body composition, sleep quality, recovery and ageing. Those were not approved uses, and they are not what its large clinical literature was built to answer.
What the research shows
Sermorelin has the largest human research record of any compound in this library that is not currently sold as a medicine. Searching PubMed on 2026-09-07 returns 445 records, of which 243 are tagged as human research and 20 are randomized controlled trials.
That is a genuinely substantial body of work, and it is important to be precise about what it is work on. The great majority of it concerns pituitary function: whether the gland responds, how much it releases, how the response changes with age and sex, and how the compound performs as a diagnostic provocation agent. It is a literature about a test, and about a deficiency, built by the people who used the drug for those things.
A large literature answering one question is not evidence about a different question. The reader who sees "445 studies" on a vendor page and concludes that adult body-composition use is well studied has made the substitution the page invited.
The same substitution runs the other way on AOD-9604, where a research file of twenty-two papers is presented as a body of fat-loss evidence and most of it is anti-doping detection chemistry.
Its regulatory history, which is unusual and often misdescribed
Sermorelin was an approved American medicine. Marketed as GEREF by EMD Serono, it holds two entries in FDA's Drugs@FDA database: NDA 019863, for a 0.05 mg ampoule, and NDA 020443, for 0.5 mg and 1 mg vials, whose original approval is dated 1997-09-26.
Both are now listed as Discontinued. And both carry a specific annotation, which we read directly from FDA's own database through its openFDA interface on 2026-09-07:
Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons.
That sentence is FDA's formal notation for a product that left the market for commercial reasons — the sponsor stopped making it — rather than because a regulator found a problem. It is a real and meaningful fact about this compound, and it is one of the few things vendors say about sermorelin that is true.
It is also routinely over-read. The determination records why the product left the market. It does not say the drug works for anything it was not approved for, it does not extend to material made by someone else, and it does not make an unapproved product legal. A drug that was approved for diagnosing pituitary function in the 1990s and left the market for business reasons is still, today, a drug with no marketed approved form.
Where it stands
Approved as a medicine: it was, in the United States, and is not now. No approved sermorelin product is currently marketed there.
Reason recorded for withdrawal: not for safety or effectiveness reasons, per the Federal Register determination noted against both applications.
Available as: compounded preparations from pharmacies, and as a research chemical. Neither is the approved product, and neither carries what an approval carries — a label, a manufacturer of record, a batch history and a regulator behind it.
Related entries in this library: tesamorelin is the analogue of the same hormone that is still an approved medicine, for one narrow use. The ghrelin-mimicking hexapeptide licensed in Japan is the other compound here with an approval behind it, and like this one it was approved partly for testing a pituitary rather than for treating a body. Ipamorelin reaches the same axis through a different receptor, with a far smaller evidence base.
Last checked
2026-09-07. FDA's Drugs@FDA records for NDA 019863 and NDA 020443 were queried through the openFDA API on that date, and the PubMed and ClinicalTrials.gov counts were run the same day.